Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2018 / May / Screen Test for Spec
Oncology Analytical science Oncology Screening and monitoring

Screen Test for Spec

How ATR-FTIR spectroscopy could lead to less invasive cancer prescreening

05/11/2018 1 min read

Share

A team from Georgia State University are using Fourier transform infrared (FTIR) spectroscopy in attenuated total reflection (ATR) mode to develop a less invasive prescreening test for melanoma and lymphoma. Here, we talk to Regents’ Professor of Physics Unil Perera about his hopes for the method.

What inspired you to develop a prescreen method?

The earlier we detect cancer, the better. Some screening methods, such as colonoscopies, are the gold standard, but are expensive and uncomfortable – to the point where patients avoid being tested. I wanted to devise a simple screening test that would be less invasive, less uncomfortable, and less costly – as well as capable of screening for more than one disease. One day, I want doctors to be able to screen patients annually; if they detect the markers for cancer, then the patient can be referred for further tests.

How far along is the work?

We have used ATR-FTIR to analyze biochemical changes in the blood serum of mouse models. We have shown in our previous work that we can identify colitis and diabetes – more recently, we were able to detect markers of lymphoma and melanoma and discriminate between healthy mice and those with tumors (1). Potentially, the technique could be applied to many different diseases – but it has yet to be proven on human samples.

What’s your ultimate aim?

We want to come up with a portable device/detector that sits in a doctor’s office. A patient gives blood, and the doctor checks for indications of a particular cancer. Our goal, ultimately, is that the doctor just needs to put in a drop of blood and get an answer – but that’s obviously some years away. Our priority right now is to prove that this works in humans.

What keeps you motivated?

I’m happy to make some contribution to human health – even a minor one. After our cancer paper was published (1), I got an email from one of our faculty members, saying that as a survivor of cancer, she was happy to see that I was doing something on early detection. That was really special.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. H Ghimire et al., “ATR-FTIR spectral discrimination between normal and tumorous mouse models of lymphoma and melanoma from serum samples”, Sci Rep, 7, 16993 (2017).

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Opening a Window into Brain Trauma
Analytical science
Opening a Window into Brain Trauma

January 18, 2024

4 min read

Raman spectroscopy shows promise as the first point-of-care diagnostic device for TBI

Could ≠ Should
Analytical science
Could ≠ Should

January 20, 2022

1 min read

The need to prevent the ordering of unnecessary tests

Diamonds Are a Diagnostician’s Best Friend
Analytical science
Diamonds Are a Diagnostician’s Best Friend

February 8, 2022

1 min read

A diagnostic sensor for rapid, cost-effective, and accurate detection of SARS-CoV-2

Hunting the Unknown
Analytical science
Hunting the Unknown

February 22, 2022

1 min read

When it comes to human health, we cannot ignore unknown molecules simply because they present analytical challenges

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.